U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Teva Pharmaceutical and Chemical (Hangzhou) Co. Ltd. - 516381 - 04/25/2018
  1. Warning Letters

CLOSEOUT LETTER

Teva Pharmaceutical and Chemical (Hangzhou) Co. Ltd. MARCS-CMS 516381 —

Recipient:
Teva Pharmaceutical and Chemical (Hangzhou) Co. Ltd.

United States

Issuing Office:

United States

 

   

Black HHS-Blue FDA Logo

 

 
 
10903 New Hampshire Avenue
Silver Spring, MD 20993 

April 25, 2018

Daniel (NMI) Chemouny
General Manager
Teva Pharmaceutical and Chemical (Hangzhou) Co. Ltd.
No. 1889 Jingliu Road, Linjiang Industrial Zone
Hangzhou, Zhejiang, 311228 P.R.C.

Reference: FEI 3009271645

Dear Mr. Chemouny:

The Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our Warning Letter: 320-17-33 dated April 5, 2017. Based on our evaluation, it appears that you have addressed the deviations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The FDA expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should deviations be observed during a subsequent inspection or through other means.

Sincerely,
/S/

Rebecca Parrilla
Compliance Officer
Division of Drug Quality I

Back to Top